Dabrafenib-d9

CAS : 1423119-98-5

Ref. TR-D101002

Informations sur le produit

• Nom: Dabrafenib-d9
• Synonymes: N-[3-[5-(2-aminopyrimidin-4-yl)-2-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]thiazol-4-yl]-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide

Description

Applications Dabrafenib-d9 is the isotope labelled analog of Dabrafenib (D101000); an inhibitor of mutated BRAF kinase. Dabrafenib also has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
References Hauschild, A., et al.: Lancet, 380, 358 (2012); Falchook, G.S., et al.: Lancet, 379, 1893 (2012); Ascierto, P.A., et al.: J. Clin. Oncol., 31, 3205 (2013)

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 528.62
• Formule: C₂₃D₉H₁₁F₃N₅O₂S₂
• Couleur/Forme: Neat
• InChI: InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)/i1D3,2D3,3D3
• Code InChI: InChIKey=BFSMGDJOXZAERB-GQALSZNTSA-N
• SMILES: [2H]C([2H])([2H])C(c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1)(C([2H])([2H])[2H])C([2H])([2H])[2H]